← All organizations
First clinical trial
Apr 1, 2004Last known activity
Apr 1, 2015
Acquired by Mirati Therapeutics Inc. → Bristol-Myers Squibb on Jun 28, 2013
Timeline
1990s
- Jun 1, 1997
MethylGene Inc.— Founded
2010s
- Jun 28, 2013
Mirati Therapeutics Inc.— Acquired By
2020s
- Oct 9, 2023
Bristol-Myers Squibb— Now
Drugs by trial phase (8 distinct, 17 trials)
Phase 2 (5 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Candidiasis
- Candidiasis, Vulvovaginal
- Carcinoma, Non-Small-Cell Lung
- Hodgkin Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Neoplasms
- Preleukemia
- Prostatic Neoplasms
- Stomach Neoplasms
- Syndrome
Recent trials (18)
- NCT02429375CollaboratorPhase 1/Phase 2Apr 1, 2015
- NCT02282358CollaboratorPhase 1/Phase 2Oct 1, 2014
- NCT01497223Study directorPhase 2Dec 1, 2011
- NCT01497223Lead sponsorPhase 2Dec 1, 2011
- NCT00975767Study directorPhase 1Aug 1, 2009
- NCT00666497Study directorPhase 2Jun 1, 2008
- NCT00679133Study directorPhase 1Apr 1, 2008
- NCT00543582Study directorPhase 2Oct 1, 2007
- NCT00511576Study directorPhase 1Aug 1, 2007
- NCT00431873Study directorPhase 2Jan 1, 2007
- NCT00374296Study directorPhase 2Sep 1, 2006
- NCT00372437Study directorPhase 1/Phase 2Sep 1, 2006
- NCT00358982Study directorPhase 2Aug 1, 2006
- NCT00359086Study directorPhase 2Aug 1, 2006
- NCT00324220Study directorPhase 1/Phase 2Jan 1, 2006
Details
- Founded
- Montreal, CA Jun 1, 1997
- Last known activity
- Apr 1, 2015